en · de · es
melanotan-2-notes.peptides7250.com › Topic › Peptide Identity And Structural Background — Explained

Peptide Identity And Structural Background — Explained

By Editorial Desk · published 2025-07-22 · last reviewed 2025-08-20 · Topic

A practical reference on synthetic peptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

Reviewed 2025-08-20. Anything still debated is marked as such rather than presented as settled.

Peptide Identity and Structural Background

Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.

The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.

Background and Chemical Profile

The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.

Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.

Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.

Melanotan-2 at a glance

PropertyValueNotes
Molecular formulaC50H69N15O9Synthetic cyclic heptapeptide
Molecular massApproximately 1024 g/molDepends on counter-ion content
AppearanceWhite to off-white powderCommonly supplied as a lyophilised solid
SolubilityFreely soluble in waterAlso dissolves in common aqueous buffers
Typical storage-20 degrees Celsius, desiccatedProtect from light and repeated freeze-thaw

Melanotan II Background and Mechanism

Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.

Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.

Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.

Related pages on this site

Background from the literature

reassociation kinetics The measurement and manipulation of the rate of reannealing of complementary strands of DNA, generally by heating and denaturing a double-stranded molecule into single strands and then observing their rehybridization at a cooler temperature. Because the base pair G+C requires more energy to anneal than the base pair A+T, the rate of reannealing between two strands depends partly on their nucleotide sequence, and it is therefore possible to predict or estimate the sequence of the duplex molecule by the time it takes to fully hybridize. Reassociation kinetics is studied with C0t analysis: fragments reannealing at low C0t values tend to have highly repetitive sequences, while higher C0t values imply more unique sequences.

== Treatment == Acute hypoglycemia is reversed by raising the blood glucose. Glucagon should be injected intramuscularly or intravenously, or dextrose can be infused intravenously to raise the blood glucose. Oral administration of glucose can worsen the outcome, as more insulin is eventually produced. Most people recover fully even from severe hypoglycemia after the blood glucose is restored to normal. Recovery time varies from minutes to hours depending on the severity and duration of the hypoglycemia. Death or permanent brain damage resembling stroke can occur rarely as a result of severe hypoglycemia. See hypoglycemia for more on effects, recovery, and risks. Further therapy and prevention depends upon the specific cause. Most hypoglycemia due to excessive insulin occurs in people who take insulin for type 1 diabetes. Management of this hypoglycemia is sugar or starch by mouth (or in severe cases, an injection of glucagon or intravenous dextrose). When the glucose has been restored, recovery is usually complete. Prevention of further episodes consists of maintaining balance between insulin, food, and exercise. Management of hypoglycemia due to treatment of type 2 diabetes is similar, and the dose of the oral hypoglycemic agent may need to be reduced. Reversal and prevention of hypoglycemia is a major aspect of the management of type 1 diabetes. Hypoglycemia due to drug overdose or effect is supported with extra glucose until the drugs have been metabolized. The drug doses or combination often needs to be altered.

In the 15th century, Cossack society was described as a federation of independent communities, which often formed local cavalry units and were entirely independent from neighboring states such as Poland, the Grand Duchy of Moscow, and the Crimean Khanate. There are confusing historical reports, according to Mykhailo Hrushevsky, that "the first mention of Cossacks dates back to the 14th century", although that seems indicative of people who were either Turkic or of undefined origin. Hrushevsky states that a deeper intuitive study of the evolution of the Cossacks indicates they may have descended from the long-forgotten Antes, or from groups from the Berlad territory of the Brodnici in present-day Romania, then a part of the Grand Duchy of Halych. There, the Cossacks may have served as self-defence formations, organized to defend against raids conducted by aggressive far-ranging tribes. The first international mention of Cossacks was in 1492, when Crimean Khan Meñli I Giray complained accusingly to Grand Duke of Lithuania Alexander Jagiellon that the Grand Duke's Cossack subjects from Kiev and Cherkasy had pillaged a Crimean Tatar ship. The duke ordered his "Ukrainian" (meaning borderland) officials to investigate, execute the guilty, and give their belongings to the Khan. Sometime in the 16th century, there appeared an old Ukrainian Ballad of Cossack Holota, about a Cossack near Kiliya. In the 16th century Cossack societies evolved into two independent territorial organizations, as well as other smaller, still-detached groups:

== Epidemiology == Biliary atresia seems to affect females slightly more often than males, and Asians and African Americans more often than Caucasians. It is common for only one child in a pair of twins or within the same family to have the condition. There seems to be no link to medications or immunizations given immediately before or during pregnancy. Diabetes during pregnancy particularly during the first trimester seems to predispose to a number of distinct congenital abnormalities in the infant such as sacral agenesis, transposition of the great vessels and the syndromic form of biliary atresia.

Drug packaging (or pharmaceutical packaging) is process of packing pharmaceutical preparations for distribution, and the physical packaging in which they are stored. It involves all of the operations from production through drug distribution channels to the end consumer. Pharmaceutical packaging is highly regulated but with some variation in the details, depending on the country of origin or the region. Several common factors can include: assurance of patient safety, assurance of the efficacy of the drug through the intended shelf life, uniformity of the drug through different production lots, thorough documentation of all materials and processes, control of possible migration of packaging components into the drug, control of degradation of the drug by oxygen, moisture, heat, light exposure etc., prevention of microbial contamination, sterility, etc. Packaging is often involved in dispensing, dosing, and use of the pharmaceutical product. Communication of proper use and cautionary labels are also regulated. Packaging is an integral part of pharmaceutical product.

Sources: en.wikipedia.org

Reference notes

into the general solution produces orbits that escape to infinity (while still satisfying the equation of motion). Substituting the definitions for the axial and cyclotron frequencies, one might also write this condition as

== Side effects == The side effects for Levonantradol include ptosis, sedation, and ataxia in non-human primates. In rodents, the symptoms include dysphoria, memory impairment, motor incoordination, reduced concentration, and disorientation. Levonantradol also decreases startle response. In humans, side effects include dry mouth, drowsiness, dizziness, altered perception, mild sedation, and lack of concentration. It can cause an increase in heart rate and decrease in blood pressure. Euphoric symptoms rarely occurred in subjects.

=== Distribution in plants === Didymin is found in a variety of citrus fruits, including mandarin oranges, sweet oranges, grapefruit, and lemons, as well as in Origanum vulgare (oregano). In immature dropped fruits of Citrus sinensis, didymin has been quantified alongside other flavanone glycosides such as hesperidin and narirutin, with its content being better preserved by freeze-drying than by hot-air oven drying. It was first identified in grapefruit as a tasteless rutinoside-type flavanone glycoside, in contrast to the bitter neohesperidoside-type glycosides such as naringin. It is also present in chenpi (dried citrus peel), a traditional ingredient in Chinese medicine.

=== Coup trap === The accumulation of previous coups is a strong predictor of future coups, a phenomenon called the coup trap. A 2014 study of 18 Latin American countries found that the establishment of open political competition helps bring countries out of the coup trap and reduces cycles of political instability.

Sources: en.wikipedia.org

Reference notes

There are three amino acids with side chains that are cations at neutral pH: arginine (Arg, R), lysine (Lys, K) and histidine (His, H). Arginine has a charged guanidino group and lysine a charged alkyl amino group, and are fully protonated at pH 7. Histidine's imidazole group has a pKa of 6.0, and is only around 10% protonated at neutral pH. Because histidine is easily found in its basic and conjugate acid forms it often participates in catalytic proton transfers in enzyme reactions.

In November 2016, India's Drug Consultative Committee announced it was embarking on establishing a definition of drugs which could be dispensed without a prescription. Prior to this, the general assumption was that any drug which did not fall into a prescription schedule could be purchased without a prescription. However, the needed definition had not been enacted by early 2018. The lack of a legal definition for OTC drugs has led to this US$4 billion market segment being effectively unregulated. In the Netherlands, there are four categories:

Measurements of 137Cs exposure from autopsies performed on 52 children who died of various causes found that the concentration of 137Cs was highest in the thyroid (2054±288 Bq/kg), adrenals (1576±290 Bq/kg), and pancreas (1359±350 Bq/kg), and lowest in the brain (385±72 Bq/kg) and liver (347±61 Bq/kg).‍ Accidental ingestion of caesium-137 can be treated with Prussian blue (FeIII4[FeII(CN)6]3), which binds to it chemically and reduces its biological half-life to 30 days.‍

Sources: en.wikipedia.org

Frequently asked questions

What is Melanotan-2 chemically?

It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.

How does it differ from the natural hormone?

It is shorter than the native hormone and carries a cyclic constraint that improves stability. These changes raise receptor potency and slow breakdown relative to the naturally occurring peptide.

When was Melanotan-2 first described?

Published accounts date its development to the 1980s, when researchers were generating analogues of melanocyte-stimulating hormone. That work aimed to produce more stable compounds for studying pigmentation biology.

What is melanotan-2?

It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.

Network